NewGenIvf Group (NASDAQ: NIVF) is a China-based platform specializing in assisted reproductive services and technologies. The company offers a comprehensive suite of fertility solutions, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), pre-implantation genetic testing (PGT), egg and sperm freezing, and donor matching. Through its network of in-house laboratories and outpatient clinics, NewGenIvf seeks to enhance patient outcomes and reduce the time to pregnancy by integrating advanced diagnostic tools, personalized treatment protocols, and data-driven monitoring systems.
Since its founding in 2020, NewGenIvf has expanded rapidly across Mainland China, establishing over 80 fertility centers in more than 40 cities. Each clinic features dedicated embryology labs staffed by certified embryologists, while clinical teams include reproductive endocrinologists, obstetricians, and genetic counselors. The company also leverages partnerships with regional hospitals and women’s health groups to extend its reach into underserved markets and foster collaborative research on novel fertility therapies.
NewGenIvf’s technology platform integrates electronic medical records, patient portal access, and telehealth consultations, enabling prospective parents to receive remote guidance, track treatment milestones, and access educational resources. The company has invested in artificial intelligence tools to analyze historical patient data for optimized stimulation protocols. Additionally, NewGenIvf conducts analytical studies on genetic screening outcomes to refine PGT accuracy and improve embryo selection methodologies.
Led by Chairman and CEO Dr. Yongliang Liu, a former reproductive endocrinologist with over two decades of clinical experience, NewGenIvf combines scientific expertise with an entrepreneurial approach to healthcare delivery. The leadership team includes Chief Medical Officer Dr. Xinru Wang and Chief Operating Officer Ms. Lijuan Chen, both of whom bring extensive backgrounds in clinical operations and patient services. As China’s fertility market continues to evolve under supportive demographic policies, NewGenIvf aims to solidify its position as a leading service provider and innovation partner in reproductive medicine.
AI Generated. May Contain Errors.